October 31, 2014 9:27 AM ET


Company Overview of Xigen SA

Company Overview

Xigen SA, a biopharmaceutical company, develops therapeutics to inhibit intracellular protein-protein interactions for the treatment of various diseases in the areas of inflammation, central nervous system, oncology, and virology, as well as cancers. Its products include XG-102, a non-ATP competitive peptide based inhibitor of c-jun N-terminal kinase (JNK) that is an intracellular therapeutic target; and XG-102 (AM-111) for acute sensorineural hearing loss. The company was founded in 2002 and is based in Lausanne, Switzerland.

17, rue des Terreaux

Lausanne,  1003


Founded in 2002


41 21 321 10 80


41 21 321 10 81

Key Executives for Xigen SA

Founder and Director
Chief Financial Officer
Director of Operations and Legal Manager
Head of Chemistry
Compensation as of Fiscal Year 2014.

Similar Private Companies By Industry

Company Name Region
Osmopharm SA Europe
Sino European Biotechnology AG Europe
EndoSpine Ltd. Europe
Arrayon Biotechnology SA Europe
TLT Medical Ltd. Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Xigen SA, please visit www.xigenpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.